

WO 2005/034923

PCT/IB2004/003542

1

SUSTAINED-RELEASE MICROGRANULES CONTAINING GINKGO BILOBA EXTRACT AND THE  
PROCESS FOR MANUFACTURING THESE

5       The subject of the present invention is a new  
stable formulation in the form of sustained-release  
microgranules containing Ginkgo Biloba extract as well  
as the process for preparing it.

10       More precisely, the present invention relates  
to microgranules in the form of a core containing  
Ginkgo Biloba extract with at least one  
pharmaceutically acceptable excipient, an intermediate  
layer coating said core, and an outer layer, which  
enables sustained release of Ginkgo Biloba from the  
core.

15       Ginkgo Biloba extract contains flavone  
glycosides (flavonoids), such as quercetin, kaemferol,  
isorhamnetin and terpenes (hétérosides) such as  
Bilobadide, ginkgolide A, ginkgolide B, ginkgolide C,  
ginkgolide J.

20       Flavonoids are known to have anti Platelet-  
activiting Factor properties, thus terpenes have  
corticoid-like, anti-ischaemic properties and are known  
to be antagonists of peripheral benzodiapine  
receptors, inducing anti-stress activity.

25       Powders extracted from plant substances are  
usually very hygroscopic and they therefore pump  
moisture from the granules and from the gelatin  
capsule, which become brittle. This leads to poor  
stability properties.

30       Plant extracts have poor flowability and  
compressibility properties. Thus, formulation of such  
extracts in the form of sustained release tablets is  
not possible, as it requires homogeneous mixtures of

extracts with pharmaceutical excipients during all compression steps.

WO 00/69414 relates to granules containing at least one plant substance, characterized in that they  
5 each comprise a neutral core, which has a grain size of between 200 and 4 000  $\mu\text{m}$  and which is coated with a layer containing the plants substance, combined with a pharmaceutically suitable excipient.

The multiparticulate form of the invention  
10 makes it possible to obtain a stable and reproducible sustained release multiparticulate dosage form comprising Gingko Biloba extract, with the advantage of being stable during storage, particularly in accelerated storage conditions, defined in ICH as 40°C  
15 for temperature and 75% for relative humidity.

According to the present invention, the sustained release microgranules contain a Gingko Biloba extract, characterized by the release of total flavone glycosides having the following profile of dissolution  
20 rates, measured at 37.0°C  $\pm$  0.5°C, with a Dissolution Test Apparatus I (Basket method at 100 rpm, 900 mL of purified water, UV Detection : 272 nm) :

T (h)	DISSOLUTION (w/w)
0,5 hour	$\leq$ 45 %
2 hours	< 75 %
8 hours	> 60 %

25 More specifically, the sustained release microgranules are characterized by the following profile :

T (h)	Dissolution (w/w)
0,5 hour	5-45 %
2 hours	30-70 %
8 hours	> 60 %

These granules containing Gingko Biloba extract are further characterized in that they comprise :

- 5        - a neutral core coated with a layer containing Gingko Biloba extract, with at least one pharmaceutically acceptable excipient,
- an optionnal water-repellent layer, coating said core, comprising at least a polymer or a
- 10        thermoplastic excipient,
- an outer polymeric layer which sustain the release of said extract from the active core.

Gingko Biloba extract may be in a concentrated preparation which are liquid, solid or of  
15 intermediate consistency, generally obtained from dried plant raw materials, preferably leaves, or in a powder form.

Fluid extracts are liquid preparations of which, in general, a portion by mass or by volume  
20 corresponds to a portion by mass of dried raw material. These preparations are adjusted, if necessary, so as to meet the requirements of content of solvents, of constituents or of dry residue.

Soft extracts are preparations having an  
25 intermediate consistency between fluid extracts and dry extracts. Soft extracts are prepared by partial evaporation of the solvent which served for their preparation. Only ethanol at an appropriate title or water is used. Soft extracts have in general a dry

residue which is not less than 70 per cent by weight. They may contain appropriate antimicrobial preservatives.

5 Dry extracts are solid preparations obtained by evaporation of the solvent which served for their production. Dry extracts have in general a dry residue which is not less than 95 per cent by weight. Appropriate inert substances may be added.

10 The plant powders are obtained from whole plants or fragmented or cut plant portions, used as they are, in desiccated form.

Ginkgo Biloba extracts contain up to 40% by weight of flavonoids, and up to 10% by weight of terpenes.

15 Preferred Ginkgo Biloba extracts contain 24% by weight of flavonoids and 6% by weight of terpenes.

The neutral core consists of a substance chosen from sugar, starch, mannitol, sorbitol, xylitol, cellulose, talc and mixtures thereof.

20 The neutral core may also consist of a starch/sucrose core in 80/20 mass ratios which is coated with 80% by weight of starch. In such neutral cores, the proportion by mass of sugar is advantageously less than 20%.

25 The layer containing the Ginkgo Biloba extract contains at least one pharmaceutically acceptable excipient, selected from the group comprising a binder, an antistatic agent or a lubricant, preferably a binder.

30 The binder is selected from the group consisting of cellulosic polymers, such as ethylcellulose, hydroxypropylcellulose and hydroxypropylmethyl cellulose, acrylic polymers, such as insoluble acrylate ammoniomethacrylate copolymer, polyacrylate as polymethacrylic copolymer, povidones,

copovidones, polyvinylalcohols, shellac, alginic acid, sodium alginate, starch, pregelatinized starch, sucrose and its derivatives, guar gum, polyethylene glycol, preferably polyvinylpyrrolidone (PVP) or shellac.

5           The binder is used in proportions of at most about 50%, preferably at most 20% by weight of Gingko Biloba extract.

          The antistatic agent, which can be used as flow aid, is selected from the group consisting of  
10   micronised or non micronised talc, fumed silica (Aerosil® R972), colloidal silica (Aerosil®200), precipitated silica (Syloid® FP244) and mixtures thereof.

          The antistatic agent is used in proportions  
15   of at most 5%, preferably 2% by weight relative to the weight of said granules of GB extract.

          The lubricant is selected from the group consisting of magnesium stearate, stearic acid, sodium stearyl fumarate, micronised polyoxyethyleneglycol  
20   (micronised Macrogol 6000), leukine, sodium benzoate and mixtures thereof.

          The amount of lubricant is from 0 to 3 %, preferably from 1 to 2 % by weight, based on the weight of the granules.

25           In order to prevent sticking between granules, mainly due to Gingko Biloba extract, it is necessary to optionally apply an intermediate layer between the active layer comprising the Gingko Biloba extract and the polymeric layer ensuring sustained  
30   release of said extract.

          Said intermediate water-repellent layer comprises at least a polymer or a thermoplastic excipient.

The polymer is selected from the group of binders, preferably PVP.

In the context of the present invention, thermoplastic excipient refers to compounds having a melting point of between 25 and 100° C. and characterized by a pasty to semi-solid consistency at temperature of about 20° C.

The thermoplastic excipient may be chosen from partially hydrogenated oils, beeswax, carnauba wax, paraffin waxes, silicone waxes, C12-C18 fatty alcohols and fatty acids, solid, semi-synthetic glycerides, glycerol monoesters, diesters or triesters, polyoxyethylene glycols and glycosylated polyoxyethylenated glycerides, preferably monostearate glyceride and mixtures thereof.

In order to ensure a sustained dissolution profile of the active substance the granules are coated with a coating composition containing at least one coating agent selected from the group consisting of cellulosic polymers, acrylic polymers, shellac and mixtures thereof.

Among cellulosic polymers, ethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose are advantageously used.

Among acrylic polymers, insoluble acrylate ammonio-methacrylate copolymer (Eudragit® RL100 or RS100 or Eudragit® RL30D or RS30D), polyacrylate (Eudragit® NE30D), or methacrylic copolymers (Eudragit® L100-55 or Eudragit® L30D, Eudragit® E100; Eudragit® EPO) are advantageously used, alone, in combination.

Optionally plasticizers, surfactants, antistatic agents or lubricants are added as coating additives.

The plasticizer is selected in the group consisting of dibutyl sebacate triacetine, triethylacetate, triethylcitrate, ethylphthalate, or mixtures thereof. The plasticizer is used in proportions of at most about 30%, preferably 10% by weight of the coating polymers.

The surfactant may be an anionic, nonionic, cationic or amphoteric surfactant.

The antistatic agent is selected from the group comprising micronised or non micronised talc, fumed silica (Aerosil® R972), colloidal silica (Aerosil®200), precipitated silica (Syloid® FP244) and mixtures thereof.

The antistatic agent is used in proportions of at most about 10%, preferably between 0 and 3% by weight, more preferably less than 1% by weight.

The lubricant is selected in the group comprising magnésium stearate, stearic acid, sodium stearyl fumarate, micronized polyoxyethyleneglycol, sodium benzoate and mixtures thereof.

Determination of workable precise proportions in any particular instance will generally be within the capability of the man skilled in the art.

All indicated proportions and relative weight ranges described above are accordingly to be understood as being indicative of preferred or individually inventive teachings only and not as limiting the invention in its broadest aspect.

The present invention also relates to a process for the preparation of the granules described above.

The process according to the invention allows better reproducibility of the proportion.

Microgranules can be manufactured by a number of different processes, for example extrusion-spheronization, fluid air bed process or a coating-pan method.

- 5           Extrusion-Spheronization is suitable for pellets with high content of active substance, but need more equipment.

For the manufacture of the granules of the invention, the coating-pan method is preferred, as it  
10 requires only simple equipment and operation.

Good sphericity and appropriate size of microgranule benefit to control drug release by coating film and to achieve good stability of the finished product.

- 15           The process for the preparation of sustained-release microgranules containing Gingko Biloba extract comprises the successive steps consisting in:

- Applying over a neutral core, a layer comprising  
20           Gingko Biloba extract, and at least one pharmaceutical excipient, preferably a binder.
- Coating said core with an intermediate layer over the  
          thus obtained granules by spraying thereon a  
          suspension, or a solution comprising a polymer or a  
          thermoplastic excipient
- 25   - Coating the thus coated granules with an outer layer  
          by spraying a suspension, a dispersion or a solution  
          of a sustained-release coating composition,
- Drying the thus obtained coated granules.

In this process, all steps can be performed in  
30 different or in the same equipment, each step being performed in the presence of a mixture of excipients which are identical or different.



The prepared coating liquid is either water-based or prepared using organic solvents, preferably isopropyl alcohol. According to an advantageous embodiment, this coating liquid is suitable to be  
5 sprayed with conventional spray layering equipment, as for example a coating pan or a fluidized air bed equipped with a top insert or bottom (würster) insert.

According to the process of the invention, the cores are obtained by powder-coating,  
10 advantageously carried out by alternately spraying an alcoholic or aqueous-alcoholic solution comprising at least one pharmaceutical excipient, preferably a binder, and the Ginkgo Biloba extract.

The granules according to the invention are  
15 prepared according to coating techniques known in the art, preferably in a pan or in a fluidized air bed.

The invention is illustrated without any limitation by the following examples.

In the examples below, the following  
20 excipients are used :

- Ginkgo Biloba extract containing 24% by weight of flavone glycosides and 6% by weight of terpene) : Zhejiang Conba Pharmaceutical Co. Ltd.
- 25 - Neutral cores : NP Pharm
- PVP K30 : Shanghai Huayi economy and trade industry of science and technology Co.Ltd.
- Shellac : Alland & Robert
- 30 - Talc : Shanghai Tianpin pharmaceutical factory
- Ethylcellulose : FMC
- Monostearate glycerides
- Dibutyl Sebacate

Dissolution Test Method

This method was developed in order to detect release of total flavone glycosides from microgranules containing Ginkgo Biloba extract.

- Apparatus : Dissolution Test Apparatus I (Basket method)
- Speed : 100 rpm
- Volume : 900 mL of purified water
- 10 - Temperature : 37.0°C ±0.5°C
- Sampling (mL): 10 mL
- UV Detection : UV at 272 nm

Water content assay

15 Water content is determined using Karl Fischer Water determination.

Content assay method

This method was developed in order to assay total flavone glycosides content from microgranules containing Ginkgo Biloba extract, and specifically assay quercetin, kaemfortol and isohamnetin content from granules.

Source : Chinese Pharmacopeia 2000 Part One, Appendix VI D

- Apparatus : HP 1100 Liquid Chromatograph (including quaternary pump, UV detector, diode array detector, chemical work station),
- Chromatographic conditions
- 30 HPLC Column : C<sub>18</sub> 4,6\*250 nm 15µm Beijing Dima
- Mobile Phase : methanol, 0,4%v/v phosphoric acid solution (50/50)
- Sampling : 10 µl
- UV Detection : 360 nm

Example 1

Step 1 - drug loading

84 Grams of neutral cores are placed in a coating-pan,  
5 A 10% (w/w) binding solution of shellac, dissolved in  
isopropyl alcohol is prepared, then sprayed over  
neutral core as Ginkgo Biloba extract is gradually  
added at the same time.

Granules are then sieved and dried for 10 hour at 60°C.

10

Step 2 - Intermediate water-repellent coating

4,8 grams of monostearate glycerides are dissolved in  
isopropyl alcohol at 10% (w/w) and the resulting  
solution is sprayed over granules from step 1.

15

Step 3 - Sustained -release coating

The thus obtained granules were coated by spraying  
thereon a water dispersion of Aquacoat ECD30 at 16 %  
(weight/weight) containing dibutyl sebacate as  
20 plasticizer (25% versus dry polymer).

The amount of coating was of 8 % by weight with respect  
to the weight of the granules from step 2.

Coated microgranules are then sieved and dried in a  
25 coating pan at 65°C for 10 hours.

The sustained-release microgranules resulting from the  
process have the following formula (table 1) :

Table 1

Name of ingredients	function	Unit formula (g)	Percentage formula (%w/w)
Ginkgo extract	Active substance	120.0	50.0
Neutral granules	Cores	84.0	35.0
Shellac	Binding agent	9.6	4.0
Aquacoat ECD30	Coating agent	16.8	7.0
Dibutyl sebacate	Plasticiser	4.1	1.7
Monstearate glyceride	Water-repellent agent	4.8	2.0
Talc	Antistatic agent	0.7	0.3
Water	Solvent	qs	/
Isopropyl alcohol	Solvent	qs	/

The dissolution rates of the thus obtained sustained-release granules were measured with the method described above :

5 The results are given in the following table 2 :

T (h)	% released(w/w)
1	21.8%
2	36.9%
4	51.5%
8	64.1%
12	70.2%

Example 2 :

## Step 1 - drug loading

498 grams of neutral cores are placed in a coating-pan.

- 5 A 10% (w/w) binding solution of PVP K30, dissolved in isopropyl alcohol is prepared, then sprayed over neutral core as Ginkgo Biloba extract is gradually added at the same time.

Granules are then sieved and dried for 10 hour at 60°C.

10

## Step 2 - Sustained -release coating

- A 10% (w/w) coating solution containing 14 grams of shellac in isopropyl alcohol is prepared and sprayed on the microgranules with spraying gun, alternatively  
15 with addition of an appropriate quantity of talc.

Coated microgranules are then sieved and dried in a coating pan at 65°C for 10 hours.

The sustained-release microgranules resulting from the process have the following formula :

20

Table 3

	Unit formula (g)	Percent formula
Ginkgo extract	498.0	49.8%
Neutral granules	418.0	41.8%
PVP K30	20.0	2%
Shellac	14.0	1.4%
Talc	50.0	5%
Isopropylic alcohol	Qs	a.q.

The dissolution rates of total flavone glycosides from the sustained-release granules were measured according to the Chinese Pharmacopeia method :

The results are given in following

5 Table 4 :

T (h)	% released(w/w)
1	20.7%
2	38.1%
4	54.4%
8	62.3%
12	69.1%

### Example 3

Sustained release microgranules comprising Ginkgo Biloba are prepared according the process of example to example 2 (see table 5) :

10 Table 5

Name of ingredients	function	Unit formula (g)	Percentage formula (%w/w)
Ginkgo extract	Active substance	120	49,8
Neutral granules	Cores	101	41,8
PVP K30	Binding agent	4,82	2
Shellac	Coating agent	3,37	1,4
Talc	Antistatic agent	12,1	5
Isopropyllic alcohol	Solvent	qs	/

Microgranules thus obtained are encapsulated in hard-gelatin capsules, each containing 120 mg of Ginkgo Biloba extract, said capsules being packed in PVC/Alu blisters.

5                   Stability of the resulting product was tested in long term conditions ( $25^{\circ}\text{C} \pm 2^{\circ}\text{C}/\text{HR}$   $60\% \pm 10\%$ ) and in accelerated conditions ( $40^{\circ}\text{C} \pm 2^{\circ}\text{C}/\text{HR}$   $75\% \pm 5\%$ ), as defined by ICH.

Results are summarized in tables 6 and 7.

10                   Conclusion : After 3 months, results comply with specifications. The microgranules remain stable in both storage conditions.

Ginkgo Biloba Capsule 120mg - Accelerate stability study

Table 6 Test results (40°C ± 2°C/HR 75% ± 5%)

Time (Month)	Water Content (%)	Appearance	Ratio of Peak Area quercetin/kae	Total Flavone Glycocides content	Dissolution (%)			Terpene Lactone content
					0.5h	2h	8h	
	<b>&lt; 9.0</b>	<b>Grey-yellow to dark brown spherical pellets</b>	<b>0.8-1.5</b>	<b>» 28.80</b>	<b>&lt; 45</b>	<b>&lt; 75</b>	<b>&gt; 60</b>	<b>/</b>
0	0.76	Passed	1.34	30.79	23.9	54.5	71.4	17.16
1	1.78	Passed	1.33	30.91	20.7	48.1	70.7	17.05
2	1.75	Passed	1.33	31.21	20.2	48.9	73.3	17.10
3	2.41	Passed	1.34	31.14	21.4	48.8	70.1	16.89

\* specifications in bold characters



Ginkgo Biloba Capsule 120mg - Long term stability study

5 Table 7 Test results (25°C ± 2°C/HR 60% ± 10%)

Time (Month)	Water Content (%)	Appearance	Ratio of Peak Area of Flavonol Aglucon	Total Flavone Glycocides content (mg/capsule)	Dissolution (%)			TerpeneLactone content (mg/capsule)
					0.5h	2h	8h	
	< 9.0	Grey-yellow to dark brown spherical pellets	0.8-1.5	» 28.80	< 45	< 75	> 60	/
0	0.76	Passed	1.34	30.79	23.9	54.5	71.4	17.16
1	1.21	Passed	1.35	31.16	26.4	54.7	70.9	17.10
2	1.75	Passed	1.34	31.88	26.0	55.4	79.2	17.04
3	1.94	Passed	1.34	31.40	26.0	55.3	75.0	17.00

\* specifications in bold characters